Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00593138 · ClinicalTrials.gov registry record · Phase 1

Study of Dopamine Transporter Receptor Occupancy With Long-acting Dex-methylphenidate

A Phase 1 study, sponsored by Massachusetts General Hospital.

Completed
Registry status
Phase 1
Development phase
23
Enrollment target

NCT00593138: Completed Phase 1 study, sponsored by Massachusetts General Hospital.

NCT00593138 is a Phase 1 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 23 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00593138, a Phase 1 study, has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
Phase 1
Development phase
23 participants
Enrollment target

Study Summary

The objectives of this study are to document the pharmacokinetics of the adequacy of DAT receptor occupancy d-MPH formulation in three doses (20 mg, 30 mg, and 40 mg) using PET scanning with C-11 Altropane as the ligand across a range of times. It has been estimated that MPH is effective when the average CNS DAT occupancy is 50% or greater. Focalin XR has been shown to be clinically effective in an analog classroom as early as 1 hour and as late as 12 hours. Therefore, it is hypothesized that the average DAT occupancy will be adequate (50% or greater) at time periods corresponding to the times of clinical efficacy. The first objective is to examine the onset of action by testing whether average DAT occupancy will be adequate (50% or greater) at 1 hour after dosing for each dose tested (20 mg, 30 mg, 40 mg). The second objective is to test the adequacy of average DAT occupancy in a range of later times for each dose. The times chosen (8, 10 and 12 hours) correspond to times Focalin XR has been shown to be clinically effective in an analogue classroom study. A range of times have been chosen since, while effective at 12 hours, the degree of clinical effectiveness decreased with later time periods. The adequacy of DAT occupancy across this range of time periods will provide important details on the in vivo molecular action of the medicine at periods of critical clinical activity. The third exploratory objective is to examine a time period later then those previously tested with the highest dose. Since the clinical effectiveness of Focalin XR has not been tested out to 14 hours, it is unknown whether it is effective at 14 hours. If Focalin XR were to be effective at 14 hours it would be more likely at the highest dose.

Interventions

  • DRUG dex-methylphenidate

Trial Details

FieldValue
Enrollment Target 23 participants
Start Date 2006-12
Est. Completion 2009-12
Phase Phase 1
Massachusetts General Hospital

2,032 total trials

What the finished NCT00593138 record still lists

NCT00593138 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (62% lower).

The record links to 0 conditions, and to 1 intervention - of which dex-methylphenidate is the first listed.

NCT00593138 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00593138 about?

NCT00593138 is a clinical study titled "Study of Dopamine Transporter Receptor Occupancy With Long-acting Dex-methylphenidate". The objectives of this study are to document the pharmacokinetics of the adequacy of DAT receptor occupancy d-MPH formulation in three doses (20 mg, 30 mg, and 40 mg) using PET scanning with C-11 Altropane as the ligand across a range of times. It has been estimated that MPH is effective when the av...

What is the current status of trial NCT00593138?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2006-12. Estimated completion is 2009-12.

What interventions are being tested in trial NCT00593138?

The interventions under investigation include: dex-methylphenidate (DRUG).

Who is sponsoring clinical trial NCT00593138?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00593138's enrollment target sits among peer trials

23 1596th of 2000 higher than 400 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03616041 · 23 participants

    Capsule Endoscopy for Severe Hematochezia

  • NCT04348747 · 23 participants · Phase 2

    Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer

  • NCT04587687 · 23 participants · Phase 2

    Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

  • NCT04715022 · 23 participants · Phase 1

    Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00593138, the US trial registry maintained by the National Library of Medicine. NCT00593138 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.